It may be speculated that measurement of GH in plasma may be useful in POTS to determine the underlying neuroendocrine alterations and aid in clinical decision-making regarding a possible pharmacological intervention or substitution. The gene discussed is GH1; the disease is postural orthostatic tachycardia syndrome.